Survey Finds Nearly 50% of Clinical Research Will Adopt Decentralized Trials Within Next Year


VivaLNK has announced the results of a survey of pharma, biotech, and clinical research professionals on their opinions about the current state of remote patient monitoring (RPM). Findings unveil significant growth and advancement of RPM technologies throughout the course of the COVID-19 pandemic.

The survey reveals that nearly half (44%) have already adopted RPM for decentralized clinical trials or have plans to within the next 12 months. The adoption of remote monitoring during trials stems largely from COVID-19, as 65% of respondents noted concerns related to the pandemic as their primary driver for using RPM technology.

For more of the survey’s findings, click here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.